Application of metabolomics in sarcoma: From biomarkers to therapeutic targets

Li, Min; Choy, Edwin; Tu, Chongqi; Hornicek, Francis J.; Duan, Zhenfeng

doi:10.1016/j.critrevonc.2017.05.003

Cited by 11 publications

(14 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35 Primarily NMR-based metabolomics was integrated with the corresponding statistical strategies and completed with independent samples to discover disease-precise variations of metabolites and, in addition, validate disorder biomarkers. 36 This is because metabolomics provides more accurate information about the biological system, 37 which can be used for disorder diagnosis 38,39 and cure, 40,41 drug toxicological mechanism analysis, 42,43 and precision medicine. 44 The aim of the present study is to use NMR as a noninvasive diagnostic tool for different cancer diseases.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic Value of¹H NMR-Based Metabolomics in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Breast Cancer

et al. 2022

View full text Add to dashboard Cite

Cancer refers to a massive number of diseases distinguished by the development of abnormal cells that divide uncontrollably and have the capability of infiltration and destroying the normal body tissue. It is critical to detect biomarkers that are early detectable and noninvasive to save millions of lives. The aim of the present work is to use NMR as a noninvasive diagnostic tool for cancer diseases. This study included 30 plasma and 21 urine samples of patients diagnosed with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), 25 plasma and 17 urine samples of patients diagnosed with breast cancer (BC), and 9 plasma and urine samples obtained from healthy individuals as controls. They were prepared for NMR measurements; then, the metabolites were identified and the data were analyzed using multivariate statistical procedures. The OPLS-DA score plots clearly discriminated ALL, AML, and BC from healthy controls. Plots of the PLS-DA loadings and S-line plots showed that all metabolites in plasma were greater in BC than in the healthy controls, whereas lactate, O-acetylcarnitine, pyruvate, trimethylamine-N-oxide (TMAO), and glucose were higher in healthy controls than in ALL and AML. On the other hand, urine samples showed lower amounts of lactate, melatonin, pyruvate, and succinate in all of the studied types of cancer when compared to those of healthy controls. 1 H NMR can be a successful and noninvasive tool for the diagnosis of different types of cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Diagnostic Value of¹H NMR-Based Metabolomics in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Breast Cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Sarcomas, displaying abnormal metabolic activity patterns, still need much efforts of exploration to link these situations to specific gene mutations (57). Common step of metabolomics analysis includes sample collection and preparation, metabolite extraction, data acquisition, analysis, and interpretation, and there are already results for OS in metabolic biomarkers of diagnosis, chemoresistance, and metastasis (58). When integrated with other omics data, there would be a better understanding of the metabolic pathways from the gene level.…”

Section: Future Perspectives and Conclusionmentioning

confidence: 99%

Application of Multi-Omics Approach in Sarcomas: A Tool for Studying Mechanism, Biomarkers, and Therapeutic Targets

Zou

Sun

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Sarcomas are rare, heterogeneous mesenchymal neoplasms with various subtypes, each exhibiting unique genetic characteristics. Although studies have been conducted to improve the treatment for sarcomas, the specific development from normal somatic cells to sarcoma cells is still unclear and needs further research. The diagnosis of sarcomas depends heavily on the pathological examination, which is yet a difficult work and requires expert analysis. Advanced treatment like precise medicine optimizes the efficacy of treatment and the prognosis of sarcoma patients, yet, in sarcomas, more studies should be done to put such methods in clinical practice. The revolution of advanced technology has pushed the multi-omics approach to the front, and more could be learnt in sarcomas with such methods. Multi-omics combines the character of each omics techniques, analyzes the mechanism of tumor cells from different levels, which makes up for the shortage of single-omics, and gives us an integrated picture of bioactivities inside tumor cells. Multi-omics research of sarcomas has reached appreciable progress in recent years, leading to a better understanding of the mutation, proliferation, and metastasis of sarcomas. With the help of multi-omics approach, novel biomarkers were found, with promising effects in improving the process of diagnosis, prognosis anticipation, and treatment decision. By analyzing large amounts of biological features, subtype clustering could be done in a better precision, which may be useful in the clinical procedure. In this review, we summarized recent discoveries using multi-omics approach in sarcomas, discussed their merits and challenges, and concluded with future perspectives of the sarcoma research.

show abstract

“…Metabolomics is a relatively new discipline to gain insight into the ongoing metabolism of biological specimens. Metabolites are an objective measurement of the phenotype of a cell, and measure the interaction of the genotype and environment of a cell [ 6 ]. Thus, metabolites may serve as biomarkers for cancer diagnosis and/or prognosis.…”

Section: Introductionmentioning

confidence: 99%

“…Thus, metabolites may serve as biomarkers for cancer diagnosis and/or prognosis. To date, metabolomic signatures have already been published for several epithelial cancers, such as colon, liver, lung, pancreatic, ovarian and breast [ 6 , 7 ]. Previous research in OS is more modest and has focused on understanding the pathogenesis and development of OS.…”

Section: Introductionmentioning

confidence: 99%

Progression-Dependent Altered Metabolism in Osteosarcoma Resulting in Different Nutrient Source Dependencies

Fritsche‐Guenther

Gloaguen

Kirchner

et al. 2020

Cancers

View full text Add to dashboard Cite

Osteosarcoma (OS) is a primary malignant bone tumor and OS metastases are mostly found in the lung. The limited understanding of the biology of metastatic processes in OS limits the ability for effective treatment. Alterations to the metabolome and its transformation during metastasis aids the understanding of the mechanism and provides information on treatment and prognosis. The current study intended to identify metabolic alterations during OS progression by using a targeted gas chromatography mass spectrometry approach. Using a female OS cell line model, malignant and metastatic cells increased their energy metabolism compared to benign OS cells. The metastatic cell line showed a faster metabolic flux compared to the malignant cell line, leading to reduced metabolite pools. However, inhibiting both glycolysis and glutaminolysis resulted in a reduced proliferation. In contrast, malignant but non-metastatic OS cells showed a resistance to glycolytic inhibition but a strong dependency on glutamine as an energy source. Our in vivo metabolic approach hinted at a potential sex-dependent metabolic alteration in OS patients with lung metastases (LM), although this will require validation with larger sample sizes. In line with the in vitro results, we found that female LM patients showed a decreased central carbon metabolism compared to metastases from male patients.

show abstract

Application of metabolomics in sarcoma: From biomarkers to therapeutic targets

Cited by 11 publications

References 58 publications

Diagnostic Value of¹H NMR-Based Metabolomics in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Breast Cancer

Diagnostic Value of¹H NMR-Based Metabolomics in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Breast Cancer

Application of Multi-Omics Approach in Sarcomas: A Tool for Studying Mechanism, Biomarkers, and Therapeutic Targets

Progression-Dependent Altered Metabolism in Osteosarcoma Resulting in Different Nutrient Source Dependencies

Contact Info

Product

Resources

About

Application of metabolomics in sarcoma: From biomarkers to therapeutic targets

Cited by 11 publications

References 58 publications

Diagnostic Value of1H NMR-Based Metabolomics in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Breast Cancer

Diagnostic Value of1H NMR-Based Metabolomics in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Breast Cancer

Application of Multi-Omics Approach in Sarcomas: A Tool for Studying Mechanism, Biomarkers, and Therapeutic Targets

Progression-Dependent Altered Metabolism in Osteosarcoma Resulting in Different Nutrient Source Dependencies

Contact Info

Product

Resources

About

Diagnostic Value of¹H NMR-Based Metabolomics in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Breast Cancer

Diagnostic Value of¹H NMR-Based Metabolomics in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Breast Cancer